JG
ADVM

Jefferies Group’s Adverum Biotechnologies ADVM Stock Holding History

Jefferies Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,788
Closed -$206K – 1999
2019
Q4 		$206K Buy
+1,788
New +$158K ﹤0.01% 2240
2018
Q2 		– Sell
-1,490
Closed -$86K – 2273
2018
Q1 		$86K Buy
+1,490
New +$92.8K ﹤0.01% 2089
2016
Q2 		– Sell
-5,000
Closed -$259K – 2096
2016
Q1 		$259K Hold
5,000
– – ﹤0.01% 1741
2015
Q4 		$476K Hold
5,000
– – ﹤0.01% 1559
2015
Q3 		$412K Buy
5,000
+2,500
+100% +$319K ﹤0.01% 1601
2015
Q2 		$406K Buy
+2,500
New +$843K ﹤0.01% 1658

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jefferies Group's ADVM Position: Q1 2020 in Review

Jefferies Group sold out of Adverum Biotechnologies (ADVM) in Q1 2020, closing a stake of 1,788 shares — an estimated $206K sold.

Jefferies Group first reported a position in ADVM in Q2 2015 and held it in 6 quarters. The position peaked at $476K in Q4 2015. 126 funds tracked by Wall St. Rank hold ADVM as of Q1 2020.

  • Jefferies Group reported no remaining Adverum Biotechnologies position as of Q1 2020 after selling out during the quarter.
  • Jefferies Group sold 1,788 Adverum Biotechnologies shares in Q1 2020, an estimated $206K.
  • Jefferies Group first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 6 quarters.
  • Jefferies Group's Adverum Biotechnologies position peaked at $476K in Q4 2015.
  • 126 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2020.

Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.